Oppenheimer Buys $407K BridgeBio Stake; Q4 Loss and 2451% Revenue Surge Forecast
Oppenheimer & Co. acquired 7,845 BridgeBio Pharma shares worth approximately $407,000 in the third quarter. BridgeBio is set to report Q4 results on February 24, with a projected $0.75 per share loss and $150.02 million in revenue, up 2,451.4% year-over-year.
1. Oppenheimer Takes Stake in BridgeBio
In the third quarter, Oppenheimer & Co. initiated a position of 7,845 BridgeBio Pharma shares, valued at roughly $407,000, according to the firm’s latest regulatory filing. This institutional investment highlights growing interest in BridgeBio’s rare disease pipeline.
2. Q4 Earnings and Revenue Outlook
BridgeBio Pharma is scheduled to release Q4 results on February 24, with analysts forecasting a $0.75 per share net loss alongside $150.02 million in revenues. If realized, the revenue figure would mark a staggering 2,451.4% increase compared to the year-ago quarter.
3. Implications for Stock Performance
The combination of a strategic institutional stake and a massive revenue boost outlook could influence investor sentiment ahead of the earnings release. Market reaction will likely hinge on whether BridgeBio’s pipeline progress justifies the expected loss and revenue surge.